🌎 Headlines and Analyst Ratings for 12/29/2025

Ratings changes for NVIDIA, Quanterix, NVIDIA, Robinhood Markets, IO Biotech, Itron, Urban Outfitters and more...Upgrade to MarketBeat All Access to get our best stock ideas, proprietary research, portfolio monitoring tools, and more.  Start Your Free Trial. Unsubscribe. View My Portfolio December 29th, 2025     Starlink's $100 Billion IPO: Your Chance to Invest Early (ad) Elon Musk's Starlink project is generating major speculation ahead of a potential IPO that some analysts believe could reach a historic $100 billion valuation. According to James Altucher, there may be a smart "backdoor" way for everyday investors to position ahead of that event without needing traditional IPO access — and he says it can be done for under $100. He's also sharing a free ticker tied to this trend for anyone who wants to take a closer look.   Click here to learn more Today's Top Stories Gold and Silver Are on Fire—These Canadian Miners Ride the Wave By Dan Schmidt  |  December 29, 2025 08:33 AM Wall Street Stock picker Names #1 Stock of 2026  (Ad) By Chaikin Analytics 5 Stocks Set to Start Strong in January and Lead Through 2026 By Thomas Hughes  |  December 29, 2025 06:02 AM Gold and Silver Exploded—Now Copper May Be the Next Big Trade By Jeffrey Neal Johnson  |  December 27, 2025 09:30 AM The memecoin opportunity I can't ignore  (Ad) By Crypto 101 Media Is MetaX a NVIDIA Threat—or Just Another DeepSeek Market Scare? By Jordan Chussler  |  December 26, 2025 03:45 PM NVIDIA's $20B Groq Deal Is a Warning Shot to AI Rivals By Jeffrey Neal Johnson  |  December 26, 2025 02:12 PM Quick Links Analyst RatingsMy MarketBeatAccount SettingsMarketBeat All AccessStock ListsStock ScreenerCalculatorsPremium ReportsBest Stocks to Buy in December Trade this between 9:30 and 10:45 am EST (ad) If you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto trades, you'll want to see my new e-book, How To Master The Retirement Trade. It reveals a simple, time-based strategy that targets trades designed to play out in as little as 11 hours — no guesswork, no hype.   Claim your free copy of How To Master The Retirement Trade now Your Watchlist Your Watchlist You have not added any stocks to your watchlist. Click here to add stocks to your watchlist [How To] Invest Pre-IPO In SpaceX With $100! (ad) For the first time ever, James Altucher – one of America's top venture capitalists – is sharing how ANYONE can get a pre-IPO stake in SpaceX… with as little as $100!   [[Click here now to view.]] Analysts' Downgrades Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock, down previously from $17.00. This represents a 1.7% upside from the current price of $14.26. View More Downgrades Executive Order 14330: Trump's Biggest Yet (ad) While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies...   Discover how to invest in the fund Trump uses to collect this income >> Analysts' New Coverage 1stdibs.com (NASDAQ:DIBS) is now covered by analysts at Northland Securities. They set a "market perform" rating and a $7.00 price target on the stock. This represents a 17.9% upside from the current price of $5.94. Fathom (NASDAQ:FTHM) is now covered by analysts at Roth Capital. They set a "buy" rating and a $2.50 price target on the stock. This represents a 133.6% upside from the current price of $1.07. Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $8.00 price target on the stock. This represents a 180.7% upside from the current price of $2.85. View More New Coverage Calendars from MarketBeat U.S. Analyst Ratings Congressional Buying Corporate Buybacks Cryptocurrencies Dividend Declarations Earnings Announcements Earnings Conference Calls FDA Calendar Gap Up/Down Stocks Insider Trades Initial Public Offerings (IPOs) Most Active Stocks Percentage Gainers/Decliners Sector Performance Short Interest Stock Splits Unusual Options Volume Unusual Trading Volume Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Thank you for subscribing to MarketBeat! MarketBeat empowers individual investors to make better investment decisions by delivering up-to-the-minute financial information and unbiased investment analysis.   If you need assistance with your newsletter, please don't hesitate to contact our U.S. based support team at contact@marketbeat.com.   If you wish to unsubscribe or change which newsletters you subscribe to, you can modify your email preferences or unsubscribe from these emails.   Copyright 2006-2025 MarketBeat Media, LLC. All rights protected. 345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. U.S.A..   From Our Partners: Front-Run Buffett's Shocking Gold Move (From Golden Portfolio)